Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study.

MedComm·2026
Same author

Cartilage-adhesive/penetrating pH-responsive polyphenol-glucosamine nanoparticles alleviate osteoarthritis by matrix remodeling and immune regulation.

Materials today. Bio·2026
Same author

Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2.

Journal of gastroenterology·2026
Same author

A Self-Powered, Cold-Responsive Pyroelectric Biointerface Restores Implant Osseoperception and Osseointegration.

Advanced healthcare materials·2026
Same author

First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations.

The New England journal of medicine·2026
Same author

Sequential bioelectric programming of Macrophages via ferroelectric nanostructured surface to combat implant infection and promote bone integration.

Biomaterials·2026

Related Experiment Video

Updated: Mar 29, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Systemic therapies for hepatocellular carcinoma.

Shaohua Ge1, Dingzhi Huang

  • 1Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National ClinicalResearch Center of Cancer, Key Laboratory of Cancer Prevention and Therapy.

Drug Discoveries & Therapeutics
|December 4, 2015
PubMed
Summary

Hepatocellular carcinoma (HCC) systemic treatments are evolving. While sorafenib was a standard, newer therapies like chemotherapy and targeted agents show promise for advanced liver cancer patients.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

918

Related Experiment Videos

Last Updated: Mar 29, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

918

Area of Science:

  • Hepatology
  • Medical Oncology
  • Cancer Research

Background:

  • Hepatocellular carcinoma (HCC) presents a significant global health challenge with high incidence and mortality rates.
  • Current HCC management involves surgery, transplantation, locoregional, and systemic therapies.

Purpose of the Study:

  • To review the landscape of systemic treatments for advanced hepatocellular carcinoma.
  • To evaluate the efficacy of targeted agents, chemotherapy, antiviral, and nutritional therapies in HCC management.

Main Methods:

  • Analysis of key clinical trials (SHARP, ORIENTAL, EACH, AGEO) and retrospective studies.
  • Comparison of sorafenib with other systemic agents and treatment modalities.

Main Results:

  • Sorafenib established as first-line therapy for advanced HCC, offering modest survival benefits.
  • Sunitinib and brivanib showed no superiority over sorafenib in first-line settings; brivanib did not improve OS in second-line.
  • Oxaliplatin- and gemcitabine-based chemotherapy regimens demonstrated efficacy; capecitabine reduced recurrence and improved survival postoperatively.
  • Retrospective data suggest some treatments may be non-inferior to sorafenib in overall survival.
  • Antiviral therapy is crucial for HBV-related HCC, reducing recurrence and prolonging survival.
  • Nutritional support is vital, tailored to individual patient factors.

Conclusions:

  • The systemic treatment of HCC is dynamic, with ongoing research into chemotherapy, targeted agents, and immunotherapy.
  • Evidence supports the efficacy of various systemic approaches beyond sorafenib, including chemotherapy and antiviral treatments.
  • Personalized nutritional interventions are essential components of comprehensive HCC care.